Peregrine Beats Shareholder Suit Over Lung Cancer Drug

Law360, Washington (August 26, 2013, 6:37 PM EDT) -- A California federal judge tossed a consolidated class action against Peregrine Pharmaceuticals Inc. on Friday, saying the investor plaintiffs didn't adequately allege that the drugmaker and its executives knowingly lied about its lung cancer drug, causing a nosedive of the company's stock price.

According to U.S. District Judge Philip S. Gutierrez, Peregrine and its top brass can't be held liable for securities fraud solely because they failed to verify clinical trial results for one of the company's signature products, bavituximab, an experimental drug for the treatment...
To view the full article, register now.




Case Information

Case Title

Nathaniel L Anderson v. Peregrine Pharmaceuticals Inc et al

Case Number



California Central

Nature of Suit



Philip S. Gutierrez

Date Filed

September 28, 2012

Law Firms


UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.